These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32561291)

  • 1. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?
    Sureda A; Alizadeh J; Nabavi SF; Berindan-Neagoe I; Cismaru CA; Jeandet P; Łos MJ; Clementi E; Nabavi SM; Ghavami S
    Eur J Pharmacol; 2020 Sep; 882():173288. PubMed ID: 32561291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
    Sternberg A; McKee DL; Naujokat C
    Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
    Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
    Elife; 2020 May; 9():. PubMed ID: 32452762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
    Rico-Mesa JS; White A; Anderson AS
    Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
    Banerjee A; Czinn SJ; Reiter RJ; Blanchard TG
    Life Sci; 2020 Aug; 255():117842. PubMed ID: 32454157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for targeting complement in COVID-19.
    Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
    EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
    Batlle D; Wysocki J; Satchell K
    Clin Sci (Lond); 2020 Mar; 134(5):543-545. PubMed ID: 32167153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
    Robson B
    Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H
    Yang G
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia.
    Rivellese F; Prediletto E
    Autoimmun Rev; 2020 Jun; 19(6):102536. PubMed ID: 32251718
    [No Abstract]   [Full Text] [Related]  

  • 15. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
    Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
    FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
    Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-κb pathways in non-pregnant and pregnant populations.
    Celik O; Celik N; Aydin S; Baysal B; Aydin S; Saglam A; Gursu Y; Dalkilic S; Ulas M; Ozcil MD; Tayyar AT; Cengiz F; Ugur K; Akkoc RF; Ersahin AA
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):221-229. PubMed ID: 32538775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
    Verkhivker G
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.